Ida Iurisci

Concentrations of galectin-3 in the sera of normal controls and cancer patients.

Ida Iurisci, Nicola Tinari, Clara Natoli et al. · PubMed · 2000 · 290 citations

Medicine, Immunology, Oncology +11

6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

Xavier Pivot, Gilles Romieu, Marc Debled et al. · The Lancet · 2019 · 128 citations

Medicine, Oncology, Breast Oncology +9

Synthetic lactulose amines: novel class of anticancer agents that induce tumor-cell apoptosis and inhibit galectin-mediated homotypic cell aggregation and endothelial cell morphogenesis

Gabriel A. Rabinovich, Albana Cumashi, Germán A. Bianco et al. · Glycobiology · 2005 · 121 citations · Full text

Life Sciences, Cancer Biology, Medicinal Chemistry +17

Improved Tumor Control through Circadian Clock Induction by Seliciclib, a Cyclin-Dependent Kinase Inhibitor

Ida Iurisci, Elisabeth Filipski, Jens Reinhardt et al. · Cancer Research · 2006 · 109 citations

Medicine, Oncology, Pharmacology +17

Synthetic inhibitors of galectin-1 and -3 selectively modulate homotypic cell aggregation and tumor cell apoptosis.

Ida Iurisci, Albana Cumashi, Andrei A. Sherman et al. · PubMed · 2009 · 61 citations · Full text

Life Sciences, Oncology, Pharmacology +13